Siramesine

Siramesine (Lu 28-179) is a potent sigma-2 receptor agonist. Siramesine has a subnanomolar affinity for sigma-2 receptors (IC50=0.12 nM) and exhibits a 140-fold selectivity for sigma-2 receptors over sigma-1 receptors (IC50=17 nM) . Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Anti-cancer activity[1][2][3].

Product Specifications

CAS Number

[147817-50-3]

Product Name Alternative

Lu 28-179

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Sigma Receptor

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/siramesine.html

Purity

98.98

Solubility

10 mM in DMSO

Smiles

FC1=CC=C(N2C=C(CCCCN3CCC4(CC3)OCC5=C4C=CC=C5)C6=C2C=CC=C6)C=C1

Molecular Formula

C30H31FN2O

Molecular Weight

454.58

Precautions

H315, H319

References & Citations

[1]Perregaard J, et al. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3- (omega-aminoalkyl) -1H-indoles. J Med Chem. 1995;38 (11) :1998-2008.|[2]Česen MH, et al. Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 2013;4 (10) :e818. Published 2013 Oct 3.|[3]Ostenfeld MS, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy. 2008;4 (4) :487-499.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Sigma 1 Receptor

Citation 01

Adv Sci (Weinh) . 2023 May;10 (13) :e2300311.|Dean Francis. 2023 Jun.|J Pharmacol Exp Ther. 2015 Aug;354 (2) :203-12. |J Am Chem Soc. 2025 Apr 9;147 (14) :11766-11776.|Patent. US20220305013A1.